Clinical Trials to Determine the Treatment Efficacy of the DETA-AP Therapy Devices for the treatment of Pelvic Inflammatory Disease (acute and chronic forms)
This research was designed to determine the efficacy of the DETA-AP therapy devices with patients suffering from a clinically diagnosed Pelvic Inflammatory Disease (PIF), associated with Chlamydia, Mycoplasma, Ureaplasma, Cytomegalovirus (CMV), herpes II, and Human Papillovirus (HPV).
There were three treatment groups:
1. GROUP 1 – took only antibiotic and antiviral prescribed medication for treating Chlamydia, Mycoplasma, Ureaplasma, Cytomegalovirus (CMV), herpes II, and Human Papillovirus (HPV).
2. GROUP 2 – A combined treatment using the same medications as above, along with the Deta AP therapy device.
3. GROUP 3 – Using only the Deta AP therapy device.
Â
The 45 women taking part in these clinical trials were aged between 18-42 years (mean: 29 years) being treated on an outpatient basis in the maternity welfare centre № 10 of the Medical and Preventive Treatment Institution of “Maternity Hospital № 4†of Nizhny Novgorod State Medical Academy, Russia. The Principal Investigator was Prof. Borovkova, Head of Department, and Dr Pershin, Assistant Head.
All the woman included in the research had been clinically diagnosed with PID (both acute and chronic) and had clinical tests indicating the presence of chlamydia, mycoplasma, ureaplasma, CMV, herpes and HPV infections. The tests were conducted using enzyme multiplied immunoassay data and fragment detection of pathogen DNA by means of PCR.
The Local Ethical Committee of the State Health Care Institution of Nizhniy Novgorod District Clinical Hospital n.a. N.A. Semashko approved these clinical trials which were voluntary.
Â
RESULTS:
The 45 women in the clinical group were divided into 2 groups:
- GROUP 1 – those that combined prescription medication with the Deta AP bioresonance therapy devices.
- GROUP 2 – those that used only the Deta AP bioresonance therapy devices
There was also a 3 group of 55 women, aged 18 – 42 years, that received only prescribed medication.
The women using the Deta AP therapy devices ran them for an average of 40 – 60 minutes – there were three programmes ran every other day along with detoxification programmes.
There were frequent clinical examinations conducted to determine progress using clinical pelvic examination, ultrasound, thermography as well as blood analysis and microbiological assay of vaginal samples.
Table 1 below describes the influence of the various treatment modalities – it is clear that the average duration of using the Deta AP devices is only 3 days, versus an average of 8 – 25 days for using medications alone or medications in combination with the Deta device:
Â
Table 1. The influence of the various treatment modalities
| Diagnosis | Quantity of Patients | Average duration of treatment – medications and Deta devices (days) | Average duration of using only DETA-AP devices (days) | Average duration of treatment using only medications (days) | ||
| Gp1 | Gp2 | Gp3 | ||||
| Clamydia | 6 | 2 | 10 | 12.2±1.4 | 3±0 | 14.53±1.7 |
| Mycplasmosis | 3 | 2 | 9 | 7.23±1.1 | 3±0 | 8±1.3 |
| Ureaplasmosis | 6 | 2 | 10 | 8.93±0.9 | 3±0 | 9.33±1.1 |
| CMV infection | 6 | 3 | 8 | 10.73±1.2 | 3±0 | 12.23±1.5 |
| HPV infection | 5 | 3 | 10 | 14.43±1.3 | 3±0 | 15.93±1.3 |
| Herpes virus | 4 | 3 | 8 | 21.3±2.7 | 3±0 | 24.53±3.0 |
CONCLUSIONS:
It is interesting to note that the overall success of treatment using only prescribed medications was about 60 – 65%. This was for the treatment of the various microorganisms in question.
When the medications were combined with the use of the Deta AP device, the treatment outcome increased to 87 – 92%.
When the Deta AP device was used alone with no medications given, the treatment outcome was 85%.
The absence of any adverse side effects using the Deta AP devices resulted in the researchers concluding that bioresonance therapy was an excellent way of treating the underlying microbial caused of Pelvic Inflammatory Disease, either in the clinical setting or at home.